Abstract
To search for potential mechanism that might alter synaptic transmission following Aβ increase we have examined the presynaptic component of transmitter release. As parameters of synaptic transmission that might underlie presynaptic mechanisms, we have used paired-pulse facilitation (PPF), post-tetanic potentiation (PTP), and synaptic fatigue (SF) at the connection between the hippocampal Schaffer-collateral pathway and CA1 pyramidal neurons in ∼5 month old double transgenic mice overexpressing the mutated form of amyloid precursor protein (APPK670N, M671L) and presenilin 1 (PS1M146V). While the presynaptic mechanisms of PPF and PTP were not compromised in the APP / PS1 mice, SF was more pronounced in the double transgenic animals. The percentage of the 40th fEPSP slope over the first during the tetanus was 18 ± 3% in APP / PS1 vs. 26 ± 2% in WT. Thus, it is likely that presynaptic mechanisms underlying SF but not PPF and PTP, may account for synaptic dysfunction in APP / PS1 mice.
Keywords: synapse, amyloid, synaptic fatigue, post-tetanic potentiation, paired pulse facilitation, neurotransmitter release, alzheimers disease
Current Alzheimer Research
Title: Synaptic Fatigue is More Pronounced in the APP/PS1 Transgenic Mouse Model of Alzheimers Disease
Volume: 2 Issue: 2
Author(s): Hong Zhang, Bing Gong, Shumin Liu, Mauro Fa, Ipe Ninan, Agnieszka Staniszewski and Ottavio Arancio
Affiliation:
Keywords: synapse, amyloid, synaptic fatigue, post-tetanic potentiation, paired pulse facilitation, neurotransmitter release, alzheimers disease
Abstract: To search for potential mechanism that might alter synaptic transmission following Aβ increase we have examined the presynaptic component of transmitter release. As parameters of synaptic transmission that might underlie presynaptic mechanisms, we have used paired-pulse facilitation (PPF), post-tetanic potentiation (PTP), and synaptic fatigue (SF) at the connection between the hippocampal Schaffer-collateral pathway and CA1 pyramidal neurons in ∼5 month old double transgenic mice overexpressing the mutated form of amyloid precursor protein (APPK670N, M671L) and presenilin 1 (PS1M146V). While the presynaptic mechanisms of PPF and PTP were not compromised in the APP / PS1 mice, SF was more pronounced in the double transgenic animals. The percentage of the 40th fEPSP slope over the first during the tetanus was 18 ± 3% in APP / PS1 vs. 26 ± 2% in WT. Thus, it is likely that presynaptic mechanisms underlying SF but not PPF and PTP, may account for synaptic dysfunction in APP / PS1 mice.
Export Options
About this article
Cite this article as:
Zhang Hong, Gong Bing, Liu Shumin, Fa Mauro, Ninan Ipe, Staniszewski Agnieszka and Arancio Ottavio, Synaptic Fatigue is More Pronounced in the APP/PS1 Transgenic Mouse Model of Alzheimers Disease, Current Alzheimer Research 2005; 2 (2) . https://dx.doi.org/10.2174/1567205053585936
DOI https://dx.doi.org/10.2174/1567205053585936 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hyperhomocysteinaemia: A Critical Review of Old and New Aspects
Current Drug Metabolism Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs
Current Medicinal Chemistry Microwave Assisted One-pot Three Component Synthesis of Novel 2-(5- Aryloxymethyl-1,3,4-thiadiazolo)-3-aryl-4-thiazolidinones
Letters in Organic Chemistry Reduction of Oxidative/Nitrosative Stress in Brain and its Involvement in the Neuroprotective Effect of n-3 PUFA in Alzheimer’s Disease
Current Alzheimer Research Neurobiology of Sleep Fragmentation: Cortical and Autonomic Markers of Sleep Disorders
Current Pharmaceutical Design Commentary: Research Highlights: IKKβ Mediates Aβ-Triggered Microglial Inflammation and Neuronal Death During Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets BACE1: Expression, Regulation, and Therapeutic Potential of the Major Alzheimer’s Disease Beta-Secretase
Current Enzyme Inhibition Baseline MRI Predictors of Conversion from MCI to Probable AD in the ADNI Cohort
Current Alzheimer Research Editorial [Hot Topic: Cardiovascular Disease: Focus on Dyslipidemia (Executive Guest Editor: I. Gouni-Berthold)]
Current Pharmaceutical Design Seeing Early Signs of Alzheimer's Disease Through the Lens of the Eye
Current Alzheimer Research Disruption of Zinc Neuromodulation by Aß Oligomers : Therapeutic Implications
Current Pharmaceutical Design Protein Kinase C Isozymes: Memory Therapeutic Potential
Current Drug Targets - CNS & Neurological Disorders Properties and Clinical Development of a Novel Coating Technology: The poly[bis(trifluoroethoxy)phosphazene]
Recent Patents on Drug Delivery & Formulation Susceptibility Genes in Hypertension
Current Pharmaceutical Design Atypical Neurotransmitters and the Neurobiology of Depression
CNS & Neurological Disorders - Drug Targets Tauopathies – Focus on Changes at the Neurovascular Unit
Current Alzheimer Research Treatment of Alzheimer's Disease: Classical Therapeutic Approach
Current Pharmaceutical Analysis The Brain Protective Effect of rTMS (Repetitive Transcranial Magnetic Stimulation) in Depression: A Mini-Review in Animal Studies
Medicinal Chemistry Off-Label Prescribing of Antipsychotics in Adults, Children and Elderly Individuals: A Systematic Review of Recent Prescription Trends
Current Pharmaceutical Design Myokines in Myogenesis and Health
Recent Patents on Biotechnology